High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications
-
November 3, 2026
Clinical Report: High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer
Background
ESR1 mutations are increasingly recognized as a mechanism of acquired resistance to endocrine therapy in hormone receptor-positive/HER2-negative metastatic breast cancer. Liquid biopsy, particularly through circulating tumor DNA (ctDNA), is becoming essential for monitoring disease evolution and guiding treatment decisions. Digital PCR (dPCR) offers high sensitivity for detecting low-frequency ESR1 mutations, making it suitable for research and potential clinical applications.
Data Highlights
No numerical data provided in the source material.
Key Findings
- ESR1 mutations are key biomarkers for acquired resistance to endocrine therapy in metastatic breast cancer.
- Digital PCR provides exceptional sensitivity and rapid turnaround for detecting low-frequency ESR1 mutations.
- A European multicenter study demonstrated the reproducibility and reliability of dPCR-based ESR1 testing across laboratories.
- Liquid biopsy is recommended for monitoring ESR1 mutations at recurrence or progression on endocrine therapy.
- FDA-approved agents targeting ESR1 mutations require detection through authorized tests.
Clinical Implications
Liquid biopsy approaches should be considered for monitoring ESR1 mutations in patients with metastatic breast cancer.
Conclusion
High-sensitivity detection of ESR1 mutations using digital PCR is a significant development in the context of metastatic breast cancer.
Related Resources & Content
- ASCO Publications, ASCO, 2026 -- Validation of a droplet digital PCR test for monitoring ESR1 ctDNA variants in blood
- The ASCO Post, ASCO Post, 2015 -- Blood Test Detects Resistance to Aromatase Inhibitors in Breast Cancer Treatment Key Points
- Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update, ASCO, 2023
- Elacestrant Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial, Journal of Clinical Oncology, 2022
- ASCO Publications — Validation of a droplet digital PCR test for monitoring ESR1 ctDNA variants in blood.
- The ASCO Post — Blood Test Detects Resistance to Aromatase Inhibitors in Breast Cancer Treatment Key Points
- Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial | Journal of Clinical Oncology
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial - PubMed
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group - Annals of Oncology
- Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy - PMC
- Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2− Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy - PMC
Based on findings from:
High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications
The Pathologist, 2026.
https://thepathologist.com/webinars/2026/high-sensitivity-esr1-detection-by-digital-pcr-in-metastatic-breast-cancer-research-samples-from-analytical-validation-to-potential-clinical-applications/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
